Bridging the Gaps in Lung Cancer | Conference

Dr Malhotra on Persisting Knowledge Gaps Surrounding the Use of ADCs in Lung Cancer

August 27th 2025

Jyoti Malhotra, MD, MPH, discusses current knowledge of ADC efficacy in patients with NSCLC and brain metastases.

Dr Abu Rous on the Timing of HER2 and MET Testing in NSCLC

August 22nd 2025

Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.

Dr Halmos on Selection Criteria for Adjuvant Therapy After Chemo/IO in NSCLC

August 19th 2025

Balazs Halmos, MD, shares suggestions regarding patient selection for adjuvant therapy after neoadjuvant chemoimmunotherapy and surgery in NSCLC.

Dr Riess on Sequencing Considerations for KRAS and BRAF Inhibitors in NSCLC

August 12th 2025

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.

Dr Salgia on Biomarker-Driven Therapies of Interest for Second-Line SCLC

July 30th 2025

Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.

Dr Kim on the Collaborative, Forward-Thinking Nature of the 2025 BTG in Lung Cancer Meeting

July 30th 2025

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

Dr Sen on the Role of Immunotherapy in SCLC

July 30th 2025

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Dr Bazhenova on Improving Biomarker Development in Lung Cancer

August 5th 2024

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Dr Florez on Addressing Key Gaps in Lung Cancer Care

August 5th 2024

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLC

August 2nd 2024

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Dr Herbst on the Evolution of Targeted Therapies for EGFR+ NSCLC

August 2nd 2024

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Dr Rotow on Challenges With Targeting CNS Metastases in Lung Cancer

August 1st 2024

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Dr Backhus on Defining Borderline-Resectable Lung Cancer

August 1st 2024

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.

Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung Cancer

July 26th 2024

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC

July 26th 2024

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

Dr Sands on the Evolving Role of ADCs in SCLC Management

July 25th 2024

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

July 25th 2024

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

July 25th 2024

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

July 25th 2024

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

July 24th 2024

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.